Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Pathogens

Improved Animal Model Established for MERS-CoV

by Global Biodefense Staff
August 25, 2014
MERS-CoV Coronavirus

National Institutes of Health (NIH) scientists have found that Middle East respiratory syndrome coronavirus (MERS-CoV) infection in marmosets closely mimics the severe pneumonia experienced by people infected with MERS-CoV, giving scientists the best animal model yet for testing potential treatments.

Researchers at NIH’s National Institute of Allergy and Infectious Diseases (NIAID) used marmosets after predicting in computer models that the animals could be infected with MERS-CoV based on the binding properties of the virus.

Rather than randomly testing animal species that might provide a better model by infecting them with MERS-CoV, researchers led by Heinz Feldmann and Vincent Munster (both from Rocky Mountain Laboratories in Hamilton, Mont.) set out to identify animals whose DPP4 protein was similar to humans, especially the part known to bind directly to the viral spike protein.

They found that marmoset DPP4 has an identical amino-acid sequence (amino acids are building blocks of proteins) to human DPP4 in the critical region. A three-dimensional model confirmed that any DPP4 amino acids that differed between the marmoset and human proteins are located away from the part of DPP4 that binds the viral spike protein.

The same NIAID group in December 2012 developed the first animal model of MERS-CoV infection using rhesus macaques. That model has proven difficult to use for evaluating potential treatments because it mimics mild to moderate human disease, and the animals quickly recover from infection.

Having thus good reasons to believe that marmosets would be susceptible to MERS-CoV infection, the researchers went on to infect nine animals with the virus. All of them got sick, and their lungs contained high loads of virus and showed signs of immune response and inflammation.

While this is an initial report and the researchers point to the need for additional experiments, they see several advantages of the marmoset over the rhesus macaque model and expect that “marmosets will serve as the animal of choice for future therapeutic studies where possible.” They also state that “the development of the more severe marmoset model will ensure a better pre-clinical analysis of treatments prior to clinical trials in humans” and express the hope that their model will make “a significant contribution to reducing the impact of MERS-CoV on global public health.”

The MERS outbreak, which began in 2012, continues throughout the Middle East. Since the outbreak began, NIAID researchers have focused on understanding how the virus causes disease and how it can be treated effectively.

As of July 23rd, the World Health Organization has reported a total of 837 human cases of MERS-CoV infection, including at least 291 deaths.

PLoS Pathogens: MERS-CoV Causes Lethal Pneumonia in the Common Marmoset

Journal of Virology:  Host species restriction of Middle East respiratory syndrome coronavirus through its receptor dipeptidyl peptidase 4

Tags: Animal ModelsCoronavirusMERS-CoV

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
The device appears smaller than a playing card, transparent, with visible channels branching off.
Medical Countermeasures

How Organ-on-a-chip Models Could Grease the Drug Development Pipeline

January 10, 2023
New Virus Discovered in Swiss Ticks
Biosurveillance

New Virus Discovered in Swiss Ticks

December 7, 2022
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC